Retransplantation for donor-derived neuroendocrine tumor
β Scribed by Rehana Begum; Denise Harnois; Raj Satyanarayana; Murli Krishna; Kevin C. Halling; George P. Kim; Justin H. Nguyen; Andrew P. Keaveny
- Publisher
- John Wiley and Sons
- Year
- 2011
- Tongue
- English
- Weight
- 278 KB
- Volume
- 17
- Category
- Article
- ISSN
- 1527-6465
- DOI
- 10.1002/lt.22196
No coin nor oath required. For personal study only.
β¦ Synopsis
Although tumor transmission through liver transplantation (LT) is a rare occurrence, the consequences can be devastating, even when a very aggressive management approach is adopted. We report the case of a donor-derived small cell neuroendocrine tumor (NET) in a patient who underwent LT for cholangiocarcinoma. Despite locoregional therapy, chemotherapy and ultimately retransplantation, the patient died from metastases. The high grade nature of the NET was the most important determinant of prognosis in this case. Our experience suggests that retransplantation for donor-derived NET should only be considered when tumor biology is favorable.
π SIMILAR VOLUMES
Metastases from neuroendocrine tumors (NET) of the gastrointestinal tract, carcinoids, and endocrine pancreatic tumors (EPT) can be limited to the liver for long periods and may have slow growth. The symptoms are often related to hormone overproduction, and debulking surgery-for example, liver resec
## Background: Neuroendocrine tumors of the gastroenteropancreatic system include pancreatic islet cell and carcinoid tumors. these tumors comprise a functionally and biologically heterogeneous group of neoplasms that rarely show reliable histopathologic signs of malignancy. no etiologic factors ar